Market Overview

Insmed Up Over 30% Following FDA Decision

Related INSM
22 Stocks Moving In Thursday's Pre-Market Session
Exclusive: Insmed CEO Lives By Motto 'There Is No Finish Line'

Insmed (NASDAQ: INSM) shareholders are having a big day. Shares are up over 33 percent after the company announced that the FDA granted Arikayce breakthrough therapy designation.

Arikayce is designed to treat lung infections; more specifically, nontuberculous mycobacterial lung disease.

Insmed further stated that the designation was based on results from the phase two trial and the company plans to meet with the FDA to form a regulation pathway.

Shares were last trading at $16.65, a 33.57 percent gain.

Posted-In: News FDA


Related Articles (INSM)

View Comments and Join the Discussion!

Partner Center